tallózása szerző szerint "Hari P"

A találatok rendezése: Rendezés: Találatok:

  • Drug Effect Prediction by Polypharmacology-Based Interaction Profiling. 
    Simon, Zoltán; Peragovics, Ágnes; Vighné Smeller, Margit Borbála; Csukly, Gábor; Tombor, László; Yang Z; Zahoranszky-Kohalmi G; Végner, László; Jelinek, Balázs; Hari P; Hetényi, Csaba; Bitter, István; Czobor, Pál; Málnási Csizmadia, András (2012)
    Most drugs exert their effects via multitarget interactions, as hypothesized by polypharmacology. While these multitarget interactions are responsible for the clinical effect profiles of drugs, current methods have failed ...
  • Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma 
    Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi, Tamás; Spencer A; Hajek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG (2017)
    The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma ...
  • Virtual affinity fingerprints for target fishing: a new application of drug profile matching. 
    Peragovics, Ágnes; Simon, Zoltán; Tombor, László; Jelinek, Balázs; Hari P; Czobor, Pál; Málnási Csizmadia, András (2013)
    We recently introduced Drug Profile Matching (DPM), a novel virtual affinity fingerprinting bioactivity prediction method. DPM is based on the docking profiles of ca. 1200 FDA-approved small-molecule drugs against a set ...